Pronova Biopharma Norge as

Morten Bryhn

Anne Kristin Holmeide

Jan Kopecky

Jenny Rosman

A method is disclosed for treatment and prevention of obesity, an overweight condition or for controlling body weight reduction, wherein an effective amount of a fatty acid composition comprising at least one of (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA) or any combinations thereof, is administered to a human or an animal. Additionally, a dietary product is disclosed, containing a fatty acid composition comprising at least one of EPA and DHA or any combinations thereof, for non-medical treatment of obesity, an overweight condition and/or for supporting and controlling body weight reduction. Finally, a method is disclosed for supplementing a dietary product with a fatty acid composition mentioned above.

Use of a fatty acid composition comprising at least one of EPA and DHA or any combinations thereof

Compounds of formula (I); wherein A fatty acid composition and a pharmaceutical composition comprising such compounds are also disclosed. The use of such compounds as medicaments, in particular for the treatment of diabetes type 2, is also disclosed.

Compounds

This invention relates to the use of a fatty acid composition comprising at least (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA), or derivatives thereof, and (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or derivatives thereof for manufacturing of a medicinal product or a food stuff for the treatment and/or prevention of amyloidos-related diseases, such as Alzheimer's disease, as well as treatment/prevention of cognitive dysfunction.

Fatty acid composition for treatment of Alzheimer's disease and cognitive dysfunction

Omega-3 lipid compounds of the general formula (I): 

Growing community of inventors

Svelvik, Norway

Morten Bryhn